TY - JOUR T1 - CRBP-1 Expression in Ovarian Cancer: A Potential Therapeutic Target JF - Anticancer Research JO - Anticancer Res SP - 3303 LP - 3312 VL - 34 IS - 7 AU - ELENA DOLDO AU - GAETANA COSTANZA AU - AMEDEO FERLOSIO AU - DANIELA PASSERI AU - SERGIO BERNARDINI AU - MARIA GIOVANNA SCIOLI AU - DONATELLA MAZZAGLIA AU - SARA AGOSTINELLI AU - DONATELLA DEL BUFALO AU - BERNARD CZERNOBILSKY AU - AUGUSTO ORLANDI Y1 - 2014/07/01 UR - http://ar.iiarjournals.org/content/34/7/3303.abstract N2 - Background/Aim: Cellular retinol binding protein-1 regulates retinol bioavailability and contributes to cell differentiation maintenance, but its role in ovarian carcinogenesis remains uncertain. We investigated CRBP-1 expression in ovarian tumors and CRBP-1 signaling-regulated pathways. Materials and Methods: We performed immunohistochemistry, methylation-specific PCR, gene copy number analysis in ovarian tumors and proliferation/apoptosis evaluation, gene array, blot and real-time PCR in CRBP-1-transfected A2780 ovarian cancer cells. Results: CRBP-1 expression was reduced or absent in G2 and G3 ovarian carcinomas. CRBP-1 silencing in 60% of G2 and 66.7% of G3 carcinomas was due to CRBP-1 promoter methylation. A2780 CRBP-1-transfected cells showed increased retinol-induced apoptosis, retinoid-induced reduced clonogenicity and down-regulation of proliferation and transcription genes, including AKT1, AKT3, EGFR, FOS, JUN, STAT1 and STAT5A. Conclusion: CRBP-1 loss in G2/G3 ovarian carcinomas and increased apoptotic susceptibility to retinoids in CRBP-1-transfected-A2780 cells suggest CRBP-1 screening as a target to ensure efficacy of an adjuvant retinoid therapy. ER -